B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

RYR1

MOLECULAR TARGET

ryanodine receptor 1

UniProt: P21817NCBI Gene: 62616 compounds

RYR1 (ryanodine receptor 1) is targeted by 6 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting RYR1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1bastadin 71.956
2Caffeine0.691
3Adenosine Triphosphate0.691
4Dantrolene Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in0.691
5Ryanodine0.691
6Suramin0.691

About RYR1 as a Drug Target

RYR1 (ryanodine receptor 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 6 compounds with documented RYR1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

RYR1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.